UCB - Bimekizumab Phase 3 Data in Hidradenitis Suppurativa Show Clinically Meaningful, Deep and Maintained Response over 48 Weeks (19.03.2023)

19 maart 2023

Ucb

Bijlagen

UCB - 8d50a5a75...